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Background: Antibiotic prophylaxis is a mainstay in sickle cell disease management. However, 
adherence is estimated at only 66%. This study aimed to develop and validate a Sickle Cell 
Antibiotic Adherence Level Evaluation (SCAALE) to promote systematic and detailed 
adherence evaluation.
Methods: A 28-item questionnaire was created, covering seven adherence areas. General 
Adherence Ratings from the parent and one health care provider and medication possession 
ratios were obtained as validation measures.
Results: Internal consistency was very good to excellent for the total SCAALE (α=0.89) and 
four of the seven subscales. Correlations between SCAALE scores and validation measures 
were strong for the total SCAALE and five of the seven subscales.
Conclusion: The SCAALE provides a detailed, quantitative, multidimensional, and global 
measurement of adherence and can promote clinical care and research.
Keywords: penicillin prophylaxis, SCAALE, newborn screening program, Sickle SAFE 
Program, hemoglobinopathy, compliance
Background
Children with sickle cell disease (SCD) have compromised splenic function that 
increases the rate of bacteremia with the ensuing risk of rapid progression to sepsis, 
septic shock, and death.1,2 Penicillin prophylaxis has become a mainstay in the man-
agement of children with SCD to prevent complications relating to infection.3 With 
the implementation of prophylactic antibiotic prescribing, the risk of bacteremia in 
febrile children with SCD has decreased from 3%–5%, as documented from 1975 to 
2002,4–10 to ,1%.2,11
Yet, in spite of penicillin’s effectiveness, adherence to the twice-daily treatment 
regimen is of enduring concern.12–22 Low adherence rates illustrate the need for an 
ongoing and systematic method to measure and understand adherence in this com-
munity with the goal of improving treatment outcomes. Even a low incidence rate 
can affect a numerically large group of children when a disorder is as prevalent as 
SCD,23,24 and rates of bacteremia as a result of nonadherence may be higher in certain 
high-risk subpopulations affected by SCD. Therefore, measurement and improvement 
of adherence offers the potential for documenting, understanding, and improving 
outcomes in high-risk subpopulations and further reducing the number of bacteremia 
cases associated with SCD.
Several methods have been used to measure adherence in SCD. These include 
medical record reviews,20 urinalysis,13,14,17,20 self-/parent-report by questionnaires, inter-
views, or visual analog scales,14,18,20,25 parent/proxy Morisky scores,25 medical provider 
reports,25 clinic visit attendance,25 medication event monitoring system (MEMS) pill 
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bottles,15 and medication possession ratios (MPRs) using 
pharmacy claims12,16,22,26 or dispensation data.19,21,25 Most of 
these measures have been validated in other clinical popula-
tions; yet, the information we can glean from them is limited. 
As Beverung et al,12 who utilized an MPR, stated, “[…] we 
cannot explain why adherence is low […]”. The MPR, for 
instance, produces an adherence rating, but does not provide 
information on (potentially modifiable) variables underly-
ing nonadherence. Also, MEMS and MPRs do not provide 
information about whether the medicine was actually given 
to the child or under what conditions. Furthermore, medical 
record reviews, urinalysis, MEMS, and MPRs are costly and 
time-intensive to obtain, reducing their feasibility for daily 
clinical use at a population level.
Furthermore, although several self- or parent-report 
scales have been used to measure the factors associated with 
antibiotic nonadherence worldwide,27 most have been used as 
outcome measures in assessment or treatment studies without 
extensive psychometric analysis to support their reliability 
and validity. One antibiotic adherence parent-report scale 
that has been extensively validated is the Parental Perception 
on Antibiotics scale, which was originally developed to 
investigate the factors related to antibiotic overuse in Saudi 
Arabia.28 The Parental Perception on Antibiotics scale has 
demonstrated good internal consistency, good face and 
construct validity, and good discriminant and convergent 
validity in parents, in particular.28–30 However, it was not 
developed for the unique cultural and situational aspects of 
care and treatment of the child with SCD.
The lack of an economically and clinically feasible 
instrument to measure penicillin prophylaxis adherence in 
SCD has resulted in almost no systematic, population-wide 
documentation or monitoring of adherence in daily clinical 
practice, despite the well-established value of penicillin 
prophylaxis for preventing infection in this at-risk population. 
This critical gap in our understanding of adherence to 
penicillin prophylaxis (and application of adherence 
knowledge to the daily clinical setting) exposes a need in 
SCD clinical management and research for a more feasible, 
clinically relevant, multidimensional measure of adherence, 
that is, one that has more layers of information than just a 
single, global score.
In light of the need for and potential benefit of a new 
multidimensional measure of adherence that is valid, of low 
cost, and provides real-time information based on the per-
spective of the individual most responsible for adherence 
(the caregiver), we developed and validated the Sickle 
Cell Antibiotic Adherence Level Evaluation (SCAALE) 
(Supplementary material). This study aimed to describe the 
psychometric properties and validity of the SCAALE and 
demonstrate its potential utility as a clinical and research 
instrument. Developed using a conceptual framework of 
adherence first utilized in hemophilia,31,32 the SCAALE is 
a brief parent/guardian-report questionnaire designed to 
evaluate specific areas of adherence, identified as subscales, 
as well as global adherence to antibiotic prophylaxis.
Methods
recruitment and procedures
The study protocol was approved by the St Vincent Hospital 
Institutional Review Board. Patients were recruited by 
Sickle SAFE (Screening, Assessment, Follow-up, and 
Education) Program coordinators during home visits or 
by telephone. All participants provided informed consent; 
parents/guardians consented for minor children. Participants 
also signed a release of information, granting permission 
to contact the patient’s pharmacy and obtain dispensation 
records for the year preceding questionnaire completion. 
The parent/guardian was then given the SCAALE with 
a demographic cover sheet and allowed as much time as 
necessary to complete the survey.
Participants
Participants were recruited from the population of patients 
enrolled in the Sickle SAFE Program, the Indiana State 
Department of Health-supported hemoglobinopathy newborn 
screening (NBS) follow-up program. This program ensures 
timely notification of affected patients, educates families 
about the confirmed diagnosis and management of the disease, 
and links families to a hematologist. All infants in Indiana 
identified by the NBS laboratory as having a hemoglobin-
opathy are enrolled in the Sickle SAFE Program. From that 
population, we recruited only patients diagnosed with hemo-
globin SS disease (Hb SS), S beta thalassemia+ (Hb S/β+ Th), 
S beta thalassemia0 (Hb S/β0 Th), or hemoglobin SC disease 
(Hb SC) who had been prescribed twice-daily antibiotic 
prophylaxis for at least 3 months (the recall period on the 
questionnaire). The study was limited to English-speaking 
patients under 6 years of age.
Measure
The SCAALE is a 28-question survey divided into seven 
(four-question) subscales (Supplementary materials for 
SCAALE items):
	 Time: Does the patient take the antibiotic on the 
prescribed days and at the prescribed times?
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	 Dose: Does the child receive the appropriate dose of 
antibiotic? Do issues related to difficulty swallowing, 
misbehavior, or trouble measuring interfere with appro-
priate dosing?
	 Pharmacy: Do pharmacy-related barriers, such as hours 
of operation and dispensation errors, limit patient 
adherence?
	 Plan: Does the patient plan appropriately to have an 
adequate supply of antibiotic to be able to adhere to the 
regimen?
	 Remember: Do issues of forgetfulness impact the 
patient’s adherence?
	 Communicate: Does the patient communicate with the 
child’s physician at appropriate times, such as when 
there are questions about the antibiotic regimen or when 
fever .101°F occurs?
	 Environment: Are there environmental factors, such as 
financial or transportation barriers, stress, and chaos, or 
lack of support that contribute to nonadherence?
An eighth (five-question) subscale, Other Caretakers, with 
questions about other caretakers responsible for administering 
the antibiotic and the effect of this on adherence, was piloted 
based on input from the patient focus group. It remains under 
further review and is excluded from this report.
Questions and subscales were rationally developed and 
revised in a five-step process to optimize content validity: 
1) initial question development by hemoglobinopathy care 
specialists; 2) question review by a parent/guardian focus 
group; 3) question revision and addition of two subscales 
(“Pharmacy” and “Other Caretakers”) based on focus group 
feedback; 4) SCAALE administration to a 34-patient pilot 
sample for preliminary reliability and validity analysis; and 
5) based on pilot sample results, slight modifications to some 
questions and to descriptive anchors for the scoring scale to 
improve sensitivity. Questions were written to reflect the 
caretaker’s actions and experiences managing a twice-daily 
antibiotic schedule.
SCAALE response options are scored on five-point Likert 
scales (“Always”, “Almost Always”, “Often”, “Sometimes”, 
“Rarely or Never”). An answer of “Always” reflects the 
“best” possible adherence for some questions and the “worst” 
possible adherence for others. Questions are scored in such a 
way that responses indicating “worst” adherence receive one 
point while responses indicating “best” adherence receive 
five points. SCAALE subscale and total scores are the 
averages of the questions comprising them and range from 
1 (least adherent) to 5 (most adherent). The survey asks the 
respondent to report adherence for the past 3 months.
Validation measures of adherence
Three adherence measures were used to demonstrate 
SCAALE construct validity: General Adherence Rating 
(GAR) by parent, GAR by health care provider, and MPR 
(see descriptions later). Because no single adherence measure 
can provide a perfect characterization of adherence (short of 
a behavior coder who directly observes the child constantly), 
an adherence measure’s validity is best captured by demon-
strating significant relations between the adherence measure 
and several other estimates of adherence.
general Adherence rating
The demographic cover sheet included a GAR scale on 
which respondents rated their global adherence level 
using a scale of 1 (“rarely or never” follows the doctor’s 
instructions for antibiotic use) to 10 (“always” follows 
the doctor’s instructions for antibiotic use). The parent 
completing the SCAALE and one health care provider per 
subject provided a GAR.
The health care provider completing the GAR was the 
individual who most closely follows the patient’s prophy-
lactic antibiotic treatment for SCD. Provider responses were 
based on a global impression of the family’s adherence. 
Similar provider-rated global impression scales are widely 
used in medicine, including visual analog scales33 and global 
impression ratings.34
The GAR has been validated in previous adherence 
research.31,32
Medication possession ratio
The MPR is a widely used adherence measure and has been 
used in several studies evaluating antibiotic adherence in 
SCD.12,16,19,21,22 Advantages of the MPR are that it does not 
rely on self-report and the data can be obtained from known 
sources. However, limitations exist. Refilling a prescription 
is not the same as ingesting it, and MPR is best calculated 
in a closed pharmacy system,35 which was not available for 
this study.
An MPR for the 3 months preceding SCAALE comple-
tion was calculated using pharmacy dispensation records. The 
MPR was the ratio of the number of days during which the 
patient had antibiotics as indicated by the number of doses 
dispensed (numerator) to the number of days in the study 
period (90 days, denominator). An MPR of 1.0 indicates 100% 
adherence in terms of prescription refills relative to medication 
prescribed, while lower MPRs indicate that less medication 
was dispensed than was prescribed (lower adherence). In some 
cases, MPRs .1.0 were observed. To reflect that MPRs .1.0 
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did not necessarily indicate greater adherence than MPRs =1.0, 
MPR values .1.0 were recoded as 1.0.
statistical analysis
The SCAALE development process followed standardized 
methodology and a protocol utilizing commonly accepted 
statistics for validation studies.36,37 The statistics reported are 
outlined later.
Descriptive statistics for scAAle item, subscale, 
and total scores
Descriptive statistics and distributions (mean, range, stan-
dard deviation [SD]) of SCAALE total and all subscale 
scores are provided. Because most subjects report adher-
ence to a medical regimen, it is not uncommon for scores 
to cluster at the upper end of the distribution.31,32 A very 
significant clustering of scores at the upper end of the dis-
tribution represents a ceiling effect. For SCAALE scores, 
ceiling effects were defined as either 90% of the answers 
on any question being the highest possible option (ie, 5) or 
SD ,0.5 and mean .4.8, which would indicate restricted 
variance.
subscale intercorrelations
Subscale intercorrelations were calculated to investigate 
relations among the different areas of adherence measured 
by SCAALE subscales. Strong subscale intercorrelations 
demonstrate convergent validity, by showing the subscales 
measure the same construct. Intercorrelations are reported as 
Pearson product-moment correlation coefficients (r), which 
range from −1.0 to +1.0; values closer to 0 reflect weaker 
relationships.
internal consistency reliability
Internal consistency reliability (ICR) is a measure of whether 
a group of questions evaluate the same defined concept. This 
was assessed for the total SCAALE and all subscales and is 
reported as Cronbach’s alpha (α). This statistic ranges from 
0.0 to 1.0; the closer to 1.0, the stronger the ICR. Given 
the short subscale length (four questions), making higher α 
more difficult to achieve, α$0.8 was considered to reflect 
excellent ICR; α=0.7–0.79, very good; α=0.6–0.69, good; 
and α=0.5–0.59, minimally acceptable.
correlations with validity measures
A valid SCAALE must accurately reflect adherence, 
shown by shared variance with other estimates of adher-
ence. One test of this is a correlation between the scale 
score and the validity measure (either GAR or MPR). 
Correlations with validity measures are reported as Pearson 
product-moment correlation coefficients (r) and associated 
P-values.
Results
Demographics
Eighty-eight families were recruited; 21 declined, primarily 
due to lack of interest in the study or a desire for privacy. 
An additional seven, who were consented by telephone, 
did not return mailed questionnaires. Of the 60 remaining, 
two participants were excluded due to age being .6 years. 
This resulted in a sample size of 58. See Table 1 for sample 
demographic and medical information.
Question- and subscale-level descriptive 
data and intercorrelations
At a question level, significant ceiling effects were found 
for 9/28 questions (three questions each from the “Dose”, 
“Pharmacy”, and “Environment” subscales). All score dis-
tributions were skewed negatively, that is, most data were at 
the high end of the distribution. Item-level data are available 
in Table S1.
Mean total SCAALE score was 4.7, with a range of 
3.14–5.00 (Table 2). Subscale mean scores ranged from 
4.4 (“Plan”) to 4.9 (“Dose” and “Environment”). The 
“Time”, “Plan”, and “Environment” subscales had the 
highest median intercorrelations with the other six sub-
scales (0.53, 0.43, and 0.40, respectively), whereas the 
“Pharmacy” (0.33) and “Communicate” (0.14) subscales 
had the lowest median intercorrelations. The SCAALE 
total score was significantly correlated with all subscales 
(median correlation =0.64, range =0.50 [Communicate] 
to 0.87 [Plan]; a table of all intercorrelations is available 
from the authors).
internal consistency reliability
ICR for the total scale was excellent at α=0.89 (Table 2). Sub-
scale ICRs were variable, ranging from excellent 0.86 (Time), 
0.83 (Communicate), and 0.82 (Plan); to very good 0.77 
(Remember); to poor 0.22 (Environment), 0.24 (Pharmacy), 
and 0.32 (Dose). Notably, subscales with poor ICR are also 
those containing the most significant ceiling effects.
Validity adherence measures
Consistent with SCAALE question and subcale ratings, GAR 
measures were significantly negatively skewed (ie, toward 
the high end of the distribution). Fifty-seven (98%) parents 
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provided GARs, with 89% rating their adherence 9 or 10 
(mean 9.5, SD 1.05). Health care provider GARs were given 
for 33 (56%) participants, with 61% receiving a score of 
9 or 10 (mean 8.8, SD 1.25). Health care providers included 
primary care providers (PCPs) (n=22, 23 subjects), hematolo-
gists (n=4, six subjects), and PCP with a focus on hematology 
(n=1, four subjects). Parent GAR correlated significantly with 
provider GAR (0.48, P,0.01).
MPRs were calculated for the 37 (64%) participants for 
whom pharmacy dispensation data were available. MPR 
ranged from 0.11 to 1.00 (mean 0.65, SD 0.30). Only 38% 
of the sample had MPRs .0.80, while 19% of the sample 
had MPRs of 0.33 or less. MPR correlated significantly with 
provider GAR (r=0.57, P,0.02), but not with parent GAR 
(r=0.24, P,0.15).
The SCAALE total score correlated significantly with 
parent GAR (r=0.69, P,0.01), provider GAR (r=0.44, 
P,0.05), and MPR (r=0.46, P,0.01). The majority of 
SCAALE subscales also correlated significantly with two 
or more of the validity measures, and the “Plan” subscale 
correlated significantly with all three validity measures. All 
SCAALE subscales with the exception of “Pharmacy” and 
“Communicate” correlated significantly with Parent GAR. 
Provider GARs were significantly correlated with the “Dose” 
and “Plan” subscales, and correlations between Provider 
GAR and the “Time” and “Communicate” subscales were 
high (P,0.06). “Time”, “Plan”, and “Environment” were 
significantly correlated with MPR (Table 3).
Discussion
Daily oral administration of prophylactic penicillin has 
significantly reduced mortality associated with bacterial 
infections in children with SCD.2,11,38 This treatment is 
recommended by the National Heart, Lung, and Blood 
Institute39 as a standard of care for children with Hb SS 
and Hb S/β0 Th under 5 years of age and in older children 
who have had a previous severe pneumococcal infection or 
have functional/surgical asplenia. It was also identified in 
2011 by a Sickle Cell Disease Expert Panel as a quality of 
care indicator rated 9 out of a possible 10 for importance.40 
However, in spite of these endorsements, the effectiveness 
of antibiotic prophylaxis for young children with SCD may 
be limited by nonadherence to the treatment recommenda-
tions of twice-daily administration. There does not currently 
Table 1 Demographics
Characteristic n
Mean age in years (standard deviation, median) 58 2.61 (1.71, 2.07)
sex, n (%) 58
Male 33 (56.9)
Female 25 (43.1)
Diagnosis, n (%) 58
hemoglobin ss disease 33 (56.9)
hemoglobin sc disease 19 (32.8)
s beta thalassemia plus 5 (8.6)
s beta thalassemia zero 1 (1.7)
Patient race/ethnicity, n (%) 58
Black/African–American, non-hispanic 50 (86.2)
Black/African–American, ethnicity  
not indicated
5 (8.6)
Other, non-hispanic 2 (3.4)
Other, hispanic 1 (1.7)
Father’s country of origin, n (%) 58
UsA 47 (81.0)
new guinea 2 (3.4)
nigeria 2 (3.4)
Togo 2 (3.4)
Other (one from each: germany, ghana,  
Mali, Puerto rico, sudan)
5 (8.6)
Mother’s country of origin, n (%) 58
UsA 47 (81.0)
new guinea 2 (3.4)
nigeria 2 (3.4)
Togo 2 (3.4)
Other (one from each: germany, ghana,  
Puerto rico, sierra leone, sudan)
5 (8.6)
Patient’s country of origin, n (%) 58
UsA 56 (96.6)
new guinea 2 (3.4)
household education, n (%) 57
less than high school diploma 7 (12.1)
high school graduate 13 (22.4)
less than 2 years of college 19 (32.8)
Associate’s degree 4 (6.9)
Bachelor’s degree 7 (12.1)
some graduate school 3 (5.2)
Master’s degree 2 (3.4)
Doctorate degree 2 (3.4)
Person completing the scale, n (%) 58
Mother 52 (89.7)
Father 3 (3.4)
grandmother 3 (3.4)
Table 2 scAAle scores and reliability
SCAALE 
section
Mean Range Standard  
deviation
Internal consistency 
reliability
Total scale 4.7 3.14–5.00 0.37 0.89
Time 4.5 1.00–5.00 0.80 0.86
Dose 4.9 3.75–5.00 0.24 0.32
Pharmacy 4.6 3.25–5.00 0.44 0.24
Plan 4.4 1.25–5.00 0.81 0.82
remember 4.7 2.75–5.00 0.49 0.77
communicate 4.6 1.00–5.00 0.77 0.83
environment 4.9 4.00–5.00 0.23 0.22
Abbreviation: scAAle, sickle cell Antibiotic Adherence level evaluation.
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exist a widely accepted, validated, clinically useful means 
specifically designed to measure the multiple dimensions of 
prophylactic antibiotic adherence in SCD. This study aimed 
to address this gap by developing and validating a standard 
measure of global and specific dimensions of prophylactic 
antibiotic adherence in SCD: the SCAALE.
In addition to providing a global view of adherence based 
on a total score, the SCAALE contains seven subscales that 
yield more specific and detailed descriptions of different 
aspects of adherence. Based on prior empirical research31,32 
and focus group data, adherence is not a simple unitary 
construct, but rather consists of, and is driven by, multiple 
related factors such as timing, dosing, planning, and access to 
medical care. Therefore, measuring the dimensions of adher-
ence in addition to a total score is important for understanding 
the underlying contributors and components of nonadher-
ence, providing a first step toward targeted interventions 
for at-risk families.
The complete 28-item SCAALE total score has both the 
strongest ICR and the strongest validity correlations with 
global measures of adherence as rated by parents, providers, 
and MPR. This is not surprising as the SCAALE total score 
captures all dimensions of adherence in a single measure, 
whereas subscales focus on specific areas of adherence that 
may be more important in some families and less important 
in others. Also, the SCAALE total score has a broader 
distribution and larger variance than the subscales because 
it consists of more items across multiple adherence areas. 
Finally, longer scales generally have larger ICR values than 
shorter scales because Cronbach’s α is partially dependent 
on the length of the scale.36
Reliability and validity of the subscales were variable, 
with some subscales showing strong ICR and validity 
(“Time”, “Plan”, “Remember”, and “Communicate”) and 
others showing questionable ICR but significant validity 
correlations (“Dose” and “Environment”). The “Pharmacy” 
subscale, on the other hand, had poor ICR and low validity 
correlations, suggesting a need for additional research. The 
“Pharmacy” subscale is nevertheless recommended for inclu-
sion in the SCAALE because of its content validity based 
on unanimous recommendation by focus group participants 
and experts in SCD pediatric clinical practice.
Parents and providers rated the study sample as highly 
adherent, as measured by GARs and the SCAALE. Studies 
utilizing urinalysis as an adherence measure have found that 
parents tend to self-report a higher level of adherence than 
is reflected in urinalysis.14,17,20 Thus, it is possible that the 
parents’ GAR was somewhat inflated. However, demographic 
and clinical care variables support a high level of adherence 
in this population. Although such high adherence ratings are 
desirable from a clinical perspective, they limit the power 
of psychometric analyses by introducing restricted range 
and ceiling effects into the analysis. As noted under ICR, 
subscales with near-ceiling effects (“Dose”, “Pharmacy”, 
“Environment”) had low ICR, likely reflecting insufficient 
variability in the sample data as opposed to poor quality of 
the subscales – a larger sample and further validation analysis 
are needed to address this question. Subscales with greater 
variability (“Time”, “Plan”, “Remember”, “Communicate”) 
had good-to-excellent ICR.
Of the subscales, “Plan” and “Time” were most consis-
tently and significantly related to the three validity measures. 
This suggests that across the entire sample, behaviors related 
to planning to have antibiotics available and administering 
them at the proper time are especially important for global 
adherence, and therefore should be core components of 
adherence measurement and intervention in this population.
Our overall findings lend themselves to several implica-
tions and recommendations. The total scale score was the 
most reliable, valid, and best index of global adherence, 
reflecting its integration of multiple dimensions of adherence. 
It showed very strong ICR and correlations of 0.44 or higher 
Table 3 correlations for scAAle scores and validation measures
SCAALE section Parent General Adherence Rating Provider General Adherence Rating Medication possession ratio
Total scale 0.687** 0.441* 0.463**
Time 0.723** 0.331 0.361*
Dose 0.315* 0.389* 0.231
Pharmacy 0.191 0.188 0.015
Plan 0.691** 0.480** 0.437**
remember 0.471** 0.131 0.140
communicate 0.230 0.338 0.298
environment 0.434** 0.081 0.364*
Notes: *P,0.05; **P,0.01.
Abbreviation: scAAle, sickle cell Antibiotic Adherence level evaluation.
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with parent GAR, provider GAR, and MPR. GAR scores 
provided by the parent did not correlate significantly with 
MPR (r=0.24, P=0.14), while SCAALE total scores based on 
parent-report did correlate significantly with MPR (r=0.46, 
P=0.004). This finding indicates that measuring global adher-
ence based on a sum of the specific domains evaluated by the 
SCAALE is superior to obtaining a single global estimate 
provided by the parent. Such a finding also demonstrates that 
the core domains of the SCAALE reflect critical adherence 
components related to MPRs.
Our approach to SCAALE validation emphasized its 
relationships with multiple other methods of estimating 
adherence, each of which has advantages and limitations. 
None of the validating measures used in this study is without 
limitations, nor do we claim that the SCAALE is a perfect 
method for determining adherence. Rather, parent-report 
of adherence has specific advantages and contributions to 
estimating adherence that cannot be obtained with other 
methods such as MPR or GAR. Furthermore, if adherence 
interventions are to target parents, it is critical to under-
stand the components and barriers to adherence based on 
their report. As a result, the SCAALE has a significant and 
important role as a parent-report measure of adherence 
to penicillin prophylaxis. We took a multisource (parent-
report vs provider-report), multimethod (questionnaire and 
prescription record) approach to obtaining other validity 
measures of adherence for the SCAALE, demonstrating 
significant relationships among adherence estimates based 
on different methods and sources.
Although health care provider ratings of adherence 
have limitations, they are correlated (albeit modestly) with 
methods of estimating adherence. For instance, Logan et al41 
found significant relationships between provider-reported 
estimates of adherence and patient adherence to different 
domains measured using the Illness Management Survey. 
Zeller et al42 found a significant correlation between the 
physicians’ predictions of adherence and MEMS measures 
of adherence. Because health care providers see a wide range 
of patients, they may be able to detect extremes in adherence 
at above chance levels, and their perspective on adherence is 
valuable since it is likely to influence their medical decision 
making and interactions with patients.43
Importantly, the high level of adherence in our sample 
may, in part, reflect the degree of resources devoted to this 
patient group, which is actively monitored, managed, and 
supported by a structured NBS follow-up program. Upon 
receiving an abnormal hemoglobin result from the NBS 
laboratory, a Sickle SAFE Program coordinator contacts 
parents by telephone to discuss the diagnosis and schedule 
a home visit. The coordinator also contacts the PCP to pro-
vide education on the importance of antibiotic prophylaxis 
and ensure the first prescription for antibiotic prophylaxis 
is written. At the first home visit, when the patient is ~3–6 
weeks of age, the coordinator delivers the first 3 months’ 
supply of penicillin, provided free of charge. During the 
same home visit, the coordinator provides education and 
training on antibiotic reconstitution and dose administration. 
Sickle SAFE participants receive regular communications 
from the coordinator and a direct line remains open for the 
participants to contact the Program staff, which includes 
the coordinator and a pediatric hematologist. Moreover, if a 
participant loses insurance coverage, the Sickle SAFE Pro-
gram provides penicillin for the uninsured period at no cost 
to ensure continuity of care. Research has shown that such 
patient-centered interactions promote adherence and lead to 
improved health outcomes.44 It is quite possible that lower 
levels of adherence would be reported in samples of patients 
who do not receive this level of support.
Some methodological considerations should be taken 
into account when interpreting results of this study. First, 
although the sample size of 58 was sufficient for psycho-
metric analysis, a larger sample would likely yield greater 
variability among scores and may result in stronger reliability 
and validity statistics. It is possible that some of the weaker 
reliability statistics were a result of insufficient variability.
A second consideration is the skewed distribution of 
SCAALE scores. We believe that this reflects the tendency 
of this particular sample to be adherent due to frequent 
patient-centered interactions with the Sickle SAFE Program 
coordinator. While this may be a positive reflection on that 
program, a less-adherent sample could produce stronger reli-
ability and validity correlations by providing a larger range 
of scores and wider distribution within the range. Similarly, 
of those patients enrolled in the Sickle SAFE Program, it is 
possible that only the most adherent chose to participate, 
introducing selection bias.
A third methodological consideration is the quality of the 
pharmacy dispensation data available for calculating MPRs. 
In spite of multiple telephone follow-ups to patients’ pharma-
cies, dispensation records were available for only 37 (64%) 
study participants. Of the data obtained, we were unable to 
differentiate instances of missing data (due to pharmacy error 
or the failure to provide a comprehensive list of pharmacies) 
from when patients were actually missing dispensations (due 
to nonadherence). To be as thorough as possible, when data 
were missing, a second attempt was made to gather the data 
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by going back to the patient and pharmacy to check for errors 
in record provision or pharmacy telephone numbers.
In order to better understand group differences between 
subjects who did and did not have available MPR data, we 
compared demographic and adherence characteristics of the 
21 subjects with no MPR data with demographic and adher-
ence characteristics of the 37 subjects who provided MPR 
data. The results showed no difference in age (t (56)=1.38, 
P=0.174) or sex (χ 2 (1)=0.001, P=1.00) between the groups. 
However, children with MPRs had higher adherence as rated 
on the SCAALE total score (t (56)=2.16, P=0.035) and parent 
GAR (t (55)=3.17, P=0.002), compared to those for whom 
we were unable to obtain MPRs (Table S1). The groups did 
not differ on provider GAR (t (31)=1.20, P=0.028). These 
differences may reflect the fact that subjects with greater 
adherence live in more organized, structured, and predictable 
settings, which are more consistent in their use of pharmacies 
and, therefore, could provide more accurate data for us to use 
in accessing pharmacy records. As a result, MPR data may 
have overrepresented subjects with good adherence, although 
there was sufficient variability in MPR scores to allow for 
significant correlations with other adherence measures. The 
overrepresentation of good adherence in MPR data would 
restrict the range of adherence and may have reduced the 
correlations between MPR and other adherence ratings. 
Therefore, MPR data in a less-adherent sample may produce 
higher correlations and stronger validity results; this should 
be investigated in future research.
A fourth consideration in the interpretation of the 
SCAALE is the rating method, which is based on parent-
report. Parent-reports are susceptible to bias and error ranging 
from social desirability to denial to poor self-awareness 
and self-monitoring. Furthermore, significant correlations 
between SCAALE scores and Parent GARs may be influ-
enced by method bias because both were completed by the 
same rater. For this reason, we obtained adherence validity 
scores from three critical perspectives: parent, provider, and 
pharmacy dispensation data. Importantly, SCAALE total 
scores correlated with all three types of validity measures, 
demonstrating that method bias from parent-report does not 
account for the validity results.
While the SCAALE demonstrates strong psychometric 
properties and fills a critical unmet need, additional research 
is needed to address some shortcomings. Additional planned 
scale development initiatives are a test–retest stability inves-
tigation and use of the SCAALE with a large, diverse group 
of treatment centers with varying NBS follow-up programs. 
Future research may also investigate relations between the 
SCAALE and other validation measures such as urinalysis, 
as well as validity of the SCAALE in non-English speaking 
samples from other countries. Also, a study is planned to 
evaluate hydroxyurea adherence using a similar parent-report 
methodological approach and including MEMS devices for 
scale validation, which, in spite of their own limitations, are 
considered by some to be the gold standard in adherence 
measurement.45
Conclusion
The SCAALE provides the first detailed, quantitative, dimen-
sional, and global measurement of adherence to antibiotic 
prophylaxis in SCD. Evidence from this study supports the 
reliability and validity of the overall 28-question scale and 
of most subscales. Development of this scale represents an 
important contribution to pediatric SCD with clear appli-
cability to clinical management, research programs, and 
state-funded NBS initiatives.
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Supplementary material
Table S1 scAAle intercorrelations between subscales
SCAALE section Time Dose Pharmacy Plan Remember Communicate Environment Total
Time 1 0.426** 0.361** 0.720** 0.654** 0.144 0.626** 0.846**
Dose 0.426** 1 0.409** 0.384** 0.250 0.093 0.357** 0.518**
Pharmacy 0.361** 0.409** 1 0.432** 0.262* 0.079 0.303* 0.551**
Plan 0.720** 0.384** 0.432** 1 0.536** 0.331* 0.435** 0.869**
remember 0.654** 0.250 0.262* 0.536** 1 0.127 0.515** 0.701**
communicate 0.144 0.093 0.079 0.331* 0.127 1 0.160 0.500**
environment 0.626** 0.357** 0.303* 0.435** 0.515** 0.160 1 0.638**
Total 0.846** 0.518** 0.551** 0.869** 0.701** 0.500** 0.638** 1
Notes: *Correlation is significant at the 0.05 level (two-tailed t-test); **correlation is significant at the 0.01 level (two-tailed t-test).
Abbreviation: scAAle, sickle cell Antibiotic Adherence level evaluation.
